Published in Mol Cell Proteomics on April 07, 2009
Structural and metabolic transitions of C4 leaf development and differentiation defined by microscopy and quantitative proteomics in maize. Plant Cell (2010) 1.58
Nucleoid-enriched proteomes in developing plastids and chloroplasts from maize leaves: a new conceptual framework for nucleoid functions. Plant Physiol (2011) 1.49
Shotgun proteomics identifies proteins specific for acute renal transplant rejection. Proteomics Clin Appl (2010) 1.20
Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics (2010) 1.14
Mechanistic peptidomics: factors that dictate specificity in the formation of endogenous peptides in human milk. Mol Cell Proteomics (2014) 0.98
Current status and advances in quantitative proteomic mass spectrometry. Int J Proteomics (2013) 0.95
Investigating endogenous peptides and peptidases using peptidomics. Biochemistry (2011) 0.91
Elevated expression levels of ANXA11, integrins β3 and α3, and TNF-α contribute to a candidate proteomic signature in urine for kidney allograft rejection. Proteomics Clin Appl (2011) 0.89
Identification of novel biomarkers for sepsis prognosis via urinary proteomic analysis using iTRAQ labeling and 2D-LC-MS/MS. PLoS One (2013) 0.88
Current peptidomics: applications, purification, identification, quantification, and functional analysis. Proteomics (2015) 0.85
Profiling the proteome in renal transplantation. Proteomics Clin Appl (2011) 0.85
Proteomics and metabolomics in renal transplantation-quo vadis? Transpl Int (2012) 0.85
Difference gel electrophoresis identifies differentially expressed proteins in endoscopically collected pancreatic fluid. Electrophoresis (2011) 0.83
Label-free proteomics reveals decreased expression of CD18 and AKNA in peripheral CD4+ T cells from patients with Vogt-Koyanagi-Harada syndrome. PLoS One (2011) 0.83
Urine proteomics and biomarkers in renal disease. Nephron Exp Nephrol (2011) 0.82
Application of proteomic analysis to the study of renal diseases. Nat Rev Nephrol (2009) 0.82
Relative quantitation of neuropeptides over a thousand-fold concentration range. J Am Soc Mass Spectrom (2012) 0.82
Profiling protease activities by dynamic proteomics workflows. Proteomics (2012) 0.80
Quantitation of endogenous peptides using mass spectrometry based methods. Curr Opin Chem Biol (2013) 0.80
Biomarkers that predict diabetic nephropathy: the long road from finding targets to clinical use. Diabetes (2012) 0.76
Proteomics for rejection diagnosis in renal transplant patients: Where are we now? World J Transplant (2016) 0.76
Urinary Kininogen-1 and Retinol binding protein-4 respond to Acute Kidney Injury: predictors of patient prognosis? Sci Rep (2016) 0.76
Label-free quantitation of phosphopeptide changes in erythrocyte membranes: towards molecular mechanisms underlying deformability alterations in stored red blood cells. Haematologica (2014) 0.75
High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI). Proteomes (2013) 0.75
An Optimized Informatics Pipeline for Mass Spectrometry-Based Peptidomics. J Am Soc Mass Spectrom (2015) 0.75
Sipa1l1 is an early biomarker of liver fibrosis in CCl4-treated rats. Biol Open (2016) 0.75
Biomarkers in renal transplantation: An updated review. World J Transplant (2017) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62
Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol (2001) 28.01
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem (1993) 27.24
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med (1999) 15.69
Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol (2006) 10.14
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol (2005) 7.52
Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics (2005) 6.37
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
A study of the quality of life and cost-utility of renal transplantation. Kidney Int (1996) 4.51
The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol (2006) 3.79
Is proteomics the new genomics? Cell (2007) 2.92
Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics (2006) 2.14
Pathophysiology of Tamm-Horsfall protein. Kidney Int (1979) 1.90
Chronic allograft nephropathy: current concepts and future directions. Transplantation (2006) 1.79
Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant (2005) 1.79
Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis (2003) 1.70
Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics (2001) 1.68
Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol (2008) 1.62
The Association of Biomolecular Resource Facilities Proteomics Research Group 2006 study: relative protein quantitation. Mol Cell Proteomics (2007) 1.53
Renal risk scores: progress and prospects. Kidney Int (2008) 1.38
Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol Cell Proteomics (2007) 1.24
Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers. Transplantation (2007) 1.21
Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line. Mol Cell Proteomics (2005) 1.20
Chronic allograft nephropathy: An update. Kidney Int (1999) 1.19
Reduction of signal suppression effects in ESI-MS using a nanosplitting device. Anal Chem (2001) 1.16
Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol (2007) 1.16
Effects of salt concentration on analyte response using electrospray ionization mass spectrometry. J Am Soc Mass Spectrom (1999) 1.12
Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol (2008) 1.11
Quantitative shotgun proteomics of enriched heterocysts from Nostoc sp. PCC 7120 using 8-plex isobaric peptide tags. J Proteome Res (2008) 1.08
Protocol biopsies in renal transplantation: research tool or clinically useful? Curr Opin Nephrol Hypertens (1998) 1.01
Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol (2001) 0.98
Effects of urinary macromolecules on hydroxyapatite crystal formation. J Am Soc Nephrol (2001) 0.94
Analysis of factors associated with complications following renal transplant needle core biopsy. Br J Urol (1994) 0.93
Tamm-Horsfall protein updated. Nephron (2000) 0.92
Detection and analysis of urinary peptides by on-line liquid chromatography and mass spectrometry: application to patients with renal Fanconi syndrome. Clin Sci (Lond) (2003) 0.91
Hyphenated mass spectrometric techniques-indispensable tools in clinical and forensic toxicology and in doping control. J Mass Spectrom (2006) 0.91
Increased urinary excretion of alpha1-microglobulin at 6 months after transplantation is associated with urinary excretion of transforming growth factor-beta1 and indicates poor long-term renal outcome. Transplantation (2004) 0.90
The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney. Kidney Int (2008) 0.89
Evaluating the accuracy of functional biomarkers for detecting histological changes in chronic allograft nephropathy. Transpl Int (2007) 0.87
Clinical urinary peptidomics: learning to walk before we can run. Clin Chem (2007) 0.84
Urinary proteomics of renal Fanconi syndrome. Contrib Nephrol (2004) 0.82
Urinary Tamm-Horsfall protein as a marker of renal transplant function. Urol Res (1994) 0.80
Extra-tubular deposits of Tamm-Horsfall protein in renal allografts. J Pathol (1983) 0.79
Tamm-Horsfall protein in urine after uninephrectomy/transplantation in kidney donors and their recipients. Scand J Urol Nephrol (1997) 0.78
Ultra-sensitive and quantitative characterization of proteomes. Mol Biosyst (2006) 0.77
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature (2008) 3.19
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
A single progenitor population switches behavior to maintain and repair esophageal epithelium. Science (2012) 2.68
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol (2013) 2.62
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33
Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat Cell Biol (2013) 2.20
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A (2007) 1.98
Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 1.93
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs (2007) 1.76
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation (2011) 1.66
Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol (2008) 1.62
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. Nephron Clin Pract (2003) 1.46
Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant (2012) 1.45
Influence of the ionic dialysance monitor on Kt measurement in hemodialysis. Am J Kidney Dis (2008) 1.39
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. Sci Signal (2013) 1.20
Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol (2004) 1.12
Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant (2004) 1.12
Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant (2002) 1.11
Feasibility of transvaginal natural orifice transluminal endoscopic surgery-assisted living donor nephrectomy: is kidney vaginal delivery the approach of the future? Eur Urol (2011) 1.05
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant (2004) 1.05
Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. Atherosclerosis (2004) 1.05
Characterization of a TiO₂ enrichment method for label-free quantitative phosphoproteomics. Methods (2011) 1.04
Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol (2007) 1.03
Current challenges in software solutions for mass spectrometry-based quantitative proteomics. Amino Acids (2012) 1.02
A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments. Mol Cell Proteomics (2010) 1.01
Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics (2012) 0.99
Quantitative amino acid and proteomic analysis: very low excretion of polypeptides >750 Da in normal urine. Kidney Int (2004) 0.99
Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int (2008) 0.97
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant (2005) 0.96
Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome. Am J Physiol Renal Physiol (2007) 0.95
Generation of induced pluripotent stem cells from human renal proximal tubular cells with only two transcription factors, OCT4 and SOX2. J Biol Chem (2012) 0.93
Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin Chem Lab Med (2011) 0.93
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia (2012) 0.93
The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation (2007) 0.90
Advances in phosphopeptide enrichment techniques for phosphoproteomics. Amino Acids (2012) 0.90
First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol (2016) 0.90
Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant (2005) 0.88
Renal transplantation in HIV-infected patients: 2010 update. Kidney Int (2011) 0.86
Sirolimus-associated testicular toxicity: detrimental but reversible. Transplantation (2012) 0.86
mTOR inhibition and erythropoiesis: microcytosis or anaemia? Nephrol Dial Transplant (2011) 0.86
Increased confidence in large-scale phosphoproteomics data by complementary mass spectrometric techniques and matching of phosphopeptide data sets. J Proteome Res (2009) 0.86
Skeletal muscle mitochondrial function is preserved in young patients with chronic renal failure. Am J Kidney Dis (2002) 0.86
Nocturnal, every-other-day, online haemodiafiltration: an effective therapeutic alternative. Nephrol Dial Transplant (2011) 0.86
Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol (2013) 0.85
KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma. J Immunol (2014) 0.85
Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation (2004) 0.85
Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction. Transplantation (2009) 0.85
Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem (2003) 0.84
Renal dysfunction in the setting of HIV/AIDS. Curr HIV/AIDS Rep (2012) 0.84
Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant (2007) 0.84
Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int Suppl (2008) 0.84
Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation (2004) 0.83
Acute sensitivity of the oral mucosa to oncogenic K-ras. J Pathol (2011) 0.83
Environmental stress affects the activity of metabolic and growth factor signaling networks and induces autophagy markers in MCF7 breast cancer cells. Mol Cell Proteomics (2014) 0.82
Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers. Transplantation (2010) 0.82
Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. Mol Genet Metab (2012) 0.82
Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transpl Int (2007) 0.82
Hepatitis C virus infection and kidney transplantation. Semin Nephrol (2002) 0.81
In-depth analysis of protein phosphorylation by multidimensional ion exchange chromatography and mass spectrometry. Methods Mol Biol (2010) 0.81
Expression of transforming growth factor-beta1 and hypoxia-inducible factor-1alpha in an experimental model of kidney transplantation. Transplantation (2003) 0.81
Long-term mycophenolate monotherapy in human leukocyte antigen (HLA)-identical living-donor kidney transplantation. Transplant Res (2014) 0.81
Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients. Nephrol Dial Transplant (2011) 0.81
Treatment with sirolimus is associated with less weight gain after kidney transplantation. Transplantation (2013) 0.81
'Old-for-old'--new strategies for renal transplantation. Nephrol Dial Transplant (2006) 0.81
Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transpl Int (2007) 0.81
Is the intracellular ATP concentration of CD4+ T-Cells a predictive biomarker of immune status in stable transplant recipients? Transplantation (2009) 0.80
Evolving trends in induction therapy. Transplant Rev (Orlando) (2009) 0.80
Sirolimus monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation--a pilot experience. Transplantation (2005) 0.80
A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Transplantation (2013) 0.79
Thrombospondin-1 mRNA expression in experimental kidney transplantation with heart-beating and non-heart-beating donors. J Nephrol (2007) 0.79
Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine. Influenza Other Respir Viruses (2012) 0.79
Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant (2006) 0.79
Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients. Transplantation (2012) 0.78
On-line haemodiafiltration with auto-substitution: assessment of blood flow changes on convective volume and efficiency. Nefrologia (2015) 0.78
Urine proteomics biomarkers in renal transplantation: an overview. Transplantation (2009) 0.78
IMAC/TiO(2) enrich for peptide modifications other than phosphorylation: implications for chromatographic choice and database searching in phosphoproteomics. Proteomics (2011) 0.78
Global profiling of protein kinase activities in cancer cells by mass spectrometry. J Proteomics (2012) 0.78
Estimation of renal allograft half-life: fact or fiction? Nephrol Dial Transplant (2011) 0.78
The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant (2007) 0.78
Analysis of molecular forms of urine Retinol-Binding Protein in Fanconi Syndrome and design of an accurate immunoassay. Clin Chim Acta (2011) 0.78
A color-coded reporter model to study the effect of immunosuppressants on CD8+ T-cell memory in antitumor and alloimmune responses. Transplantation (2013) 0.78
Sensitivity of blood volume monitoring for fluid status assessment in hemodialysis patients. Blood Purif (2013) 0.77
Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial Transplant (2006) 0.77
Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk. Nefrologia (2012) 0.77
T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diagn Ther (2007) 0.77
Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients. Transplantation (2012) 0.77
Prevalence and clinical characteristics of renal transplant patients with true resistant hypertension. J Hypertens (2015) 0.77
Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth. Biochem J (2013) 0.77
Early-onset anemia after kidney transplantation is an independent factor for graft loss: a multicenter, observational cohort study. Transplantation (2013) 0.77
Mid-dilution hemodiafiltration: a comparison with pre- and postdilution modes using the same polyphenylene membrane. Blood Purif (2009) 0.76
Renal transplantation from donors with a positive serology for hepatitis C. Contrib Nephrol (2012) 0.76
The search for a new marker of renal function in older patients with chronic kidney disease stages 3-4: usefulness of cystatin C-based equations. Nephron Clin Pract (2009) 0.76